Terminated PHASE3 INTERVENTIONAL 2-arm NCT01578785

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (GLOW)

A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5ml New Formulation Administered Daily by Subcutaneous Injection

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Conditions Relapsing-Remitting Multiple Sclerosis

Interventions Glatiramer Acetate Placebo

Updated 8 times since 2017 Last updated: Feb 19, 2014 Started: Mar 31, 2012 Primary completion: Oct 31, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Teva Branded Pharmaceutical Products R&D, Inc.

More terminations from Teva Branded Pharmaceutical Products R&D, Inc.

Other Relapsing-Remitting Multiple Sclerosis trials with similar outcome

Browse all Relapsing-Remitting Multiple Sclerosis trials

Listed as NCT01578785, this PHASE3 trial focuses on Relapsing-Remitting Multiple Sclerosis and remains terminated or withdrawn. Sponsored by Teva Branded Pharmaceutical Products R&D, Inc., it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jan 2022 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Branded Pharmaceutical Products R&D, Inc.

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Athens, Greece , Barnaul, Russia , Belgrade, Serbia , Bialystok, Poland , Bihać, Bosnia and Herzegovina , Blagoevgrad, Bulgaria , Bucharest, Romania , Centennial, United States , Charlotte, United States and 105 more locations